- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07655869
[177Lu]Lu-DOTA-EB-RGD2 Therapy in Patients With Recurrent High-grade Glioma
An Investigator-Initiated Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Preliminary Efficacy of [177Lu]Lu-DOTA-EB-RGD2 in Patients With Recurrent High-grade Glioma
Studienübersicht
Status
Intervention / Behandlung
Detaillierte Beschreibung
This is a multicenter, open-label, Phase I dose-escalation study with two parallel routes of administration: intravenous (IV) and locoregional (via Ommaya reservoir into the tumor cavity). The primary objective is to determine the maximum tolerated dose (MTD) of [177Lu]Lu-DOTA-EB-RGD2 for each route using a standard "3+3" design. Three dose levels per cycle are planned for each route (IV and locoregional). Treatment is given every 3 weeks for up to 2 cycles, with possible additional cycles based on clinical benefit as judged by the investigator.
Primary endpoint: Dose-limiting toxicity (DLT) incidence during the first 6 weeks (2 cycles), graded by CTCAE v5.0.
Secondary endpoints: Adverse events (type, frequency, severity); time-activity curves and absorbed radiation doses in organs and tumors (based on whole-body planar imaging and SPECT/CT at multiple time points); pharmacokinetic parameters (AUC, Cmax, Tmax, clearance [CL], volume of distribution [Vz], terminal half-life) from blood and urine sampling; objective response rate (ORR) per RANO 2.0 (by contrast-enhanced MRI); overall survival.
Exploratory endpoints: Change in tumor αvβ3 integrin expression by NOTA-PRGD2 PET/CT; correlation between baseline NOTA-PRGD2 PET uptake and treatment response.
Sample size: Approximately 24 patients (up to 3+3 per dose level per route) using the 3+3 rule. No formal hypothesis testing is planned; descriptive statistics will be used.
Study duration: 36 months (recruitment approximately 12 months, treatment and follow-up approximately 24 months). The trial is conducted at Beijing Tiantan Hospital and Peking Union Medical College Hospital, China.
Studientyp
Einschreibung (Geschätzt)
Phase
- Frühphase 1
Kontakte und Standorte
Studienkontakt
- Name: Li'ao Wang, M.D.
- Telefonnummer: +86 15001171671
- E-Mail: wangliao17@163.com
Studieren Sie die Kontaktsicherung
- Name: Deling Li, M.D.
- E-Mail: lideling@bjtth.org
Studienorte
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 100070
- Rekrutierung
- Beijing Tiantan Hospital, Capital Medical University
-
Hauptermittler:
- Deling Li, M.D.
-
Kontakt:
- Li'ao Wang, M.D.
- Telefonnummer: 15001171671
- E-Mail: wangliao17@163.com
-
Beijing, Beijing Municipality, China, 100730
- Rekrutierung
- Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
-
Kontakt:
- Zhaohui Zhu, M.D.
- Telefonnummer: +86 15909835868
- E-Mail: 13611093752@163.com
-
Hauptermittler:
- Zhaohui Zhu, M.D.
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Beschreibung
Inclusion Criteria:
- The participant must sign the informed consent form before participation.
- Age ≥ 18 years.
- Histologically confirmed glioblastoma (WHO classification) after surgical resection or biopsy.
- Participants receiving corticosteroids (e.g., dexamethasone) must be on a stable or decreasing dose ≤ 4 mg/day (or equivalent) for at least 7 days before start of study treatment.
Adequate bone marrow and organ function confirmed by laboratory tests performed ≤ 14 days before first study treatment:
Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹/L; Platelet count ≥ 100 × 10⁹/L; Hemoglobin ≥ 10.0 g/dL; Serum creatinine ≤ 1.5 × upper limit of normal (ULN); Total bilirubin ≤ 1.5 × ULN; albumin ≥ 30 g/L; ALT and AST < 3 × ULN in absence of liver metastases, or < 5 × ULN if liver metastases present; Coagulation: activated partial thromboplastin time (APTT) ≤ 2 × ULN, international normalized ratio (INR) ≤ 1.5 (if not receiving anticoagulation therapy);
- Evidence of disease progression (PD) by RANO 2.0 criteria confirming recurrence: ≥ 25% increase in product of perpendicular diameters or > 40% increase in tumor volume compared to baseline after initial treatment or best response, while on stable or increasing corticosteroid dose. Clinical deterioration or increased corticosteroid dose alone is insufficient. MRI contrast enhancement, MRS, and/or metabolic PET should help differentiate true progression from radiation necrosis/pseudoprogression. Also, at least one bi-dimensionally measurable contrast-enhancing lesion with shortest diameter ≥ 10 mm must be present on MRI.
- For participants receiving Ommaya reservoir implantation for locoregional administration, surgery must be completed at least 2 weeks before first radionuclide therapy, with no postoperative complications. Baseline MRI for efficacy assessment must be performed at least 2 weeks after implantation and before first radionuclide therapy.
- Tumor uptake confirmed by NOTA-PRGD2 PET/CT after diagnosis of recurrence and before radionuclide therapy. For participants with Ommaya reservoir, PET/CT must be performed at least 2 weeks after implantation and before first radionuclide therapy.
- Life expectancy > 6 months.
- Karnofsky Performance Status (KPS) score ≥ 50.
Exclusion Criteria:
- Receiving any other concurrent treatment for glioblastoma outside this study.
- Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed from the start of [177Lu]Lu-DOTA-EB-RGD2 treatment until 6 months after treatment.
- Refusal to use effective contraception during sexual intercourse from informed consent until 6 months after the last dose of study drug.
- Inability to tolerate imaging procedures, repeated blood sampling, or poor venous access.
- Cardiac dysfunction, clinically significant cardiac disease history, or ECG abnormalities indicating a major safety risk, including:
(1) Documented myocardial infarction, angina pectoris, cardiomyopathy, symptomatic pericarditis, or coronary artery bypass grafting within 6 months before enrollment.
(2) Long QT syndrome, family history of idiopathic sudden death or congenital long QT syndrome, or any of the following: (a) risk factors for torsade de pointes (TdP) including uncorrected hypocalcemia, hypokalemia, hypomagnesemia, history of heart failure, or clinically significant/symptomatic bradycardia; (b) use of medications known to prolong the QT interval and/or cause TdP that cannot be discontinued or replaced with a safer alternative (e.g., within 5 half-lives or 7 days before study drug); (c) inability to determine the Fridericia-corrected QT interval (QTcF).
(3) Clinically significant arrhythmia (e.g., ventricular tachycardia), complete left bundle branch block, high-grade atrioventricular block (e.g., bifascicular block, Mobitz type II, third-degree AV block).
(4) Resting QTcF ≥ 450 ms (male) or ≥ 460 ms (female). (5) Left ventricular ejection fraction (LVEF) < 50% by echocardiography. (6) Uncontrolled hypertension defined as systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 100 mmHg, regardless of antihypertensive use.
6. Other malignancy within 5 years before study drug administration, except adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer after curative surgery, carcinoma in situ after curative surgery, or papillary thyroid cancer after curative surgery (hormonal therapy for non-metastatic prostate or breast cancer allowed).
7. Abnormal serum virology (HBsAg, T. pallidum antibody, HIV antibody, HCV antibody). Patients with untreated active hepatitis B who are willing to receive anti-HBV therapy during study treatment are allowed; patients with inactive hepatitis B are allowed; patients with inactive hepatitis C (HCV antibody positive but HCV RNA below lower limit of detection) are allowed.
8. Use of bevacizumab for glioblastoma or supportive care (e.g., edema reduction) within 60 days before start of study treatment.
9. Patients with disease progression within the first 12 weeks after completion of radiotherapy are excluded from recurrent disease trials.
10. Prior intracranial locoregional drug therapy before [177Lu]Lu-DOTA-EB-RGD2 treatment.
11. Active intracranial or intratumoral hemorrhage detected by CT/MRI. 12. Seizure within 14 days before start of study treatment; epilepsy or increased intracranial pressure uncontrolled by medication.
13. Grade 4 myelosuppression from prior anticancer therapy that has not recovered within 2 weeks, or grade 3 myelosuppression requiring >6 weeks to recover.
14. Blood transfusion within 4 weeks before screening to meet eligibility criteria.
15. Known hypersensitivity or delayed allergic reaction to any component of [177Lu]Lu-DOTA-EB-RGD2 or similar drugs.
16. Severe disease of the cardiac, respiratory, central nervous system, renal, hepatic, or other organ systems that, in the investigator's opinion, may increase participant safety risk.
17. Active infection requiring intravenous antibiotics (bacterial, fungal, or viral) within 4 weeks before first dose, or any other uncontrolled active infection deemed clinically significant by the investigator.
18. History of drug or alcohol abuse within one year before screening, long-term drug use, or psychiatric illness that may affect compliance.
19. Participation in another investigational drug or device trial within 4 weeks before first dose.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Nicht randomisiert
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Intravenous Administration of [177Lu]Lu-DOTA-EB-RGD2
Participants receive [177Lu]Lu-DOTA-EB-RGD2 via intravenous infusion 20-30 minutes once every 3 weeks (Q3W) for up to 2 cycles (6 weeks).
Dose escalation follows a 3+3 design with three dose levels per cycle.
Additional cycles may be given based on clinical benefit.
|
A long-circulating radiolabeled peptide targeting integrin αvβ3.
The radiopharmaceutical consists of an RGD2 peptide conjugated to a DOTA chelator and an albumin-binding (EB) motif, labeled with Lutetium-177 (half-life 6.7 days).
It is administered intravenously (20-30 min infusion) or locoregionally via Ommaya reservoir directly into the tumor cavity.
The study evaluates safety, tolerability, dosimetry, and preliminary efficacy in recurrent high-grade glioma.
|
|
Experimental: Locoregional Administration of [177Lu]Lu-DOTA-EB-RGD2
Participants receive [177Lu]Lu-DOTA-EB-RGD2 directly into the tumor cavity through a previously implanted Ommaya reservoir once every 3 weeks (Q3W) for up to 2 cycles (6 weeks).
Dose escalation follows a 3+3 design with three dose levels per cycle.
Additional cycles may be given based on clinical benefit.
|
A long-circulating radiolabeled peptide targeting integrin αvβ3.
The radiopharmaceutical consists of an RGD2 peptide conjugated to a DOTA chelator and an albumin-binding (EB) motif, labeled with Lutetium-177 (half-life 6.7 days).
It is administered intravenously (20-30 min infusion) or locoregionally via Ommaya reservoir directly into the tumor cavity.
The study evaluates safety, tolerability, dosimetry, and preliminary efficacy in recurrent high-grade glioma.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Incidence of Dose-Limiting Toxicities (DLTs)
Zeitfenster: Within 6 weeks (42 days) after the first dose (during the first two cycles; each cycle is 21 days)
|
DLTs are defined as protocol-specified adverse events occurring during the first 6 weeks (2 cycles) after the first dose, graded by NCI CTCAE v5.0. DLTs include: Grade ≥3 neurological toxicities (e.g., grade 3 CNS necrosis, grade 3 decreased consciousness, grade 3 hydrocephalus, grade 3 seizure, grade 3 headache that lasts over 24 hours with treatments, grade ≥4 cerebral edema); Grade ≥3 hematologic toxicities (e.g., grade 3 febrile neutropenia, grade 3 anemia lasting >7 days, grade 3 lymphopenia with infection, grade 4 neutropenia lasting >7 days, grade 4 thrombocytopenia or grade 3 with bleeding); Any grade ≥3 non-hematologic toxicity (except transient grade 3 nausea/vomiting/diarrhea lasting <3 days, grade 3 fatigue lasting <1 week, or electrolyte abnormality lasting less than 72 hours and resolved by supportive care); Any Hy's law event (e.g., ALT or AST > 3-fold upper limit normal); Death or significant clinical intervention related to the study drug. |
Within 6 weeks (42 days) after the first dose (during the first two cycles; each cycle is 21 days)
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Incidence and severity of adverse events (AEs)
Zeitfenster: From the first dose (Day 1) until study completion (up to 17 months)
|
All adverse events (AEs), serious AEs (SAEs), treatment-emergent AEs (TEAEs), and deaths, graded by NCI CTCAE v5.0.
Assessment includes changes in vital signs, physical examination, electrocardiogram (ECG), echocardiogram (for participants >60 years), laboratory tests (hematology, serum chemistry, coagulation, urinalysis), and serum pregnancy test (for females of childbearing potential).
AE resolution or progression is tracked throughout follow-up.
|
From the first dose (Day 1) until study completion (up to 17 months)
|
|
Radiation Dosimetry
Zeitfenster: From the first dose up to 192 hours (Day 8)
|
Time-activity curves (TACs) derived from whole-body planar imaging and SPECT/CT at multiple time points post-injection.
Absorbed doses to the tumor and major organs are calculated using the MIRD methodology.
|
From the first dose up to 192 hours (Day 8)
|
|
Maximum Tolerated Dose (MTD)
Zeitfenster: Within 6 weeks (42 days) after the first dose
|
The highest dose level at which ≤1 of 6 participants experiences a DLT during the first 6 weeks (2 cycles), determined separately for the intravenous and locoregional administration arms using the 3+3 dose-escalation design.
|
Within 6 weeks (42 days) after the first dose
|
|
Area Under the Concentration-Time Curve (AUC) of [177Lu]Lu-DOTA-EB-RGD2 in Blood
Zeitfenster: Pre-dose; 5, 15, 30, 60 minutes; 2, 4, 24, 48, 72, 144, 192 hours post-dose (first cycle only; each cycle is 21 days)
|
AUC calculated from time zero to last measurable time point and/or to infinity, measured from venous blood samples.
|
Pre-dose; 5, 15, 30, 60 minutes; 2, 4, 24, 48, 72, 144, 192 hours post-dose (first cycle only; each cycle is 21 days)
|
|
Objective Response Rate (ORR)
Zeitfenster: Baseline, Day 22 (±3 days), Day 42 (±7 days), then every 6 weeks until progression, death, or start of new therapy (up to 17 months)
|
Proportion of participants achieving complete response (CR) or partial response (PR) on contrast-enhanced MRI according to RANO 2.0 criteria.
CR is defined as disappearance of all enhancing and non-enhancing lesions without new lesions; PR is defined as a ≥50% decrease in the product of perpendicular diameters from baseline.
|
Baseline, Day 22 (±3 days), Day 42 (±7 days), then every 6 weeks until progression, death, or start of new therapy (up to 17 months)
|
|
Overall Survival (OS)
Zeitfenster: From the first dose up to 17 months (study duration)
|
Time from the first dose of [177Lu]Lu-DOTA-EB-RGD2 to death from any cause.
Participants alive at study end or lost to follow-up are censored at their last known alive date.
|
From the first dose up to 17 months (study duration)
|
|
Maximum Plasma Concentration (Cmax) of [177Lu]Lu-DOTA-EB-RGD2 in Blood
Zeitfenster: Pre-dose; 5, 15, 30, 60 minutes; 2, 4, 24, 48, 72, 144, 192 hours post-dose (first cycle only; each cycle is 21 days)
|
Cmax directly observed from concentration-time data, measured from venous blood samples.
|
Pre-dose; 5, 15, 30, 60 minutes; 2, 4, 24, 48, 72, 144, 192 hours post-dose (first cycle only; each cycle is 21 days)
|
|
Time to Maximum Plasma Concentration (Tmax) of [177Lu]Lu-DOTA-EB-RGD2 in Blood
Zeitfenster: Pre-dose; 5, 15, 30, 60 minutes; 2, 4, 24, 48, 72, 144, 192 hours post-dose (first cycle only; each cycle is 21 days)
|
Tmax corresponding to Cmax, measured from venous blood samples.
|
Pre-dose; 5, 15, 30, 60 minutes; 2, 4, 24, 48, 72, 144, 192 hours post-dose (first cycle only; each cycle is 21 days)
|
|
Systemic Clearance (CL) of [177Lu]Lu-DOTA-EB-RGD2 in Blood
Zeitfenster: Pre-dose; 5, 15, 30, 60 minutes; 2, 4, 24, 48, 72, 144, 192 hours post-dose (first cycle only; each cycle is 21 days)
|
CL calculated as Dose/AUC, measured from venous blood samples.
|
Pre-dose; 5, 15, 30, 60 minutes; 2, 4, 24, 48, 72, 144, 192 hours post-dose (first cycle only; each cycle is 21 days)
|
|
Volume of Distribution During Terminal Phase (Vz) of [177Lu]Lu-DOTA-EB-RGD2 in Blood
Zeitfenster: Pre-dose; 5, 15, 30, 60 minutes; 2, 4, 24, 48, 72, 144, 192 hours post-dose (first cycle only; each cycle is 21 days)
|
Vz calculated as CL/λz, measured from venous blood samples.
|
Pre-dose; 5, 15, 30, 60 minutes; 2, 4, 24, 48, 72, 144, 192 hours post-dose (first cycle only; each cycle is 21 days)
|
|
Terminal Half-Life (t1/2) of [177Lu]Lu-DOTA-EB-RGD2 in Blood
Zeitfenster: Pre-dose; 5, 15, 30, 60 minutes; 2, 4, 24, 48, 72, 144, 192 hours post-dose (first cycle only; each cycle is 21 days)
|
t1/2 calculated from the terminal phase of the concentration-time curve, measured from venous blood samples.
|
Pre-dose; 5, 15, 30, 60 minutes; 2, 4, 24, 48, 72, 144, 192 hours post-dose (first cycle only; each cycle is 21 days)
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Change in Tumor Uptake of NOTA-PRGD2 on PET/CT
Zeitfenster: Baseline (within 42 days before the first dose) and Day 42 (±7 days) after the first dose
|
Changes in tumor SUVmax, SUVmean, and tumor-to-background ratio (TBR) from baseline to post-treatment PET/CT scans, as an exploratory biomarker of target engagement.
|
Baseline (within 42 days before the first dose) and Day 42 (±7 days) after the first dose
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Deling Li, M.D., Beijing Tiantan Hospital
- Hauptermittler: Zhaohui Zhu, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Andere Studien-ID-Nummern
- BRWEP2024W032040206
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur [177Lu]Lu-DOTA-EB-RGD2
-
Peking Union Medical College HospitalRekrutierungNeuroendokrine TumorenChina
-
Peking Union Medical College HospitalNational Institute for Biomedical Imaging and Bioengineering (NIBIB)UnbekanntNeuroendokrine TumorenChina
-
The First Affiliated Hospital of Xiamen UniversityAbgeschlossenRefraktärer solider TumorChina
-
Molecular Targeting Technologies, Inc.ClinSmartRekrutierungNeuroendokrine TumorenVereinigte Staaten
-
University of California, DavisNational Institutes of Health (NIH)RekrutierungMetastasierender KrebsVereinigte Staaten
-
The First Affiliated Hospital of Xiamen UniversityAbgeschlossenRefraktäres Schilddrüsenkarzinom | Refraktäres papilläres Karzinom der Schilddrüse | Refraktäres follikuläres Schilddrüsenkarzinom | Refraktäres Hurthle-Cell-Karzinom der SchilddrüseChina
-
University of California, DavisRekrutierungLokal fortgeschrittenes Adenokarzinom des Pankreas | Metastasierter BauchspeicheldrüsenkrebsVereinigte Staaten
-
National Institute of Diabetes and Digestive and...Noch keine RekrutierungSchilddrüsenkrebsVereinigte Staaten
-
University of California, DavisUnited States Department of DefenseRekrutierungMetastasierter nichtkleinzelliger LungenkrebsVereinigte Staaten
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)ZurückgezogenMetastasierendes Phäochromozytom der Nebenniere | Stadium III Medulläres Schilddrüsenkarzinom AJCC v8 | Medulläres Schilddrüsenkarzinom im Stadium IV AJCC v8 | Lokal fortgeschrittenes Phäochromozytom der Nebenniere | Lokal fortgeschrittenes Paragangliom | Metastasierendes Paragangliom | Metastasierendes... und andere BedingungenVereinigte Staaten